| 9.08 -0.34 (-3.61%) | 03-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.7 | 1-year : | 13.09 |
| Resists | First : | 10.01 | Second : | 11.21 |
| Pivot price | 9.93 |
|||
| Supports | First : | 8.07 | Second : | 6.72 |
| MAs | MA(5) : | 9.98 |
MA(20) : | 9.68 |
| MA(100) : | 7.62  |
MA(250) : | 5.88 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 63.5 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 12.89 | Low : | 2.14 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KLRS ] has closed above bottom band by 24.7%. Bollinger Bands are 16.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.16 - 10.25 | 10.25 - 10.31 |
| Low: | 8.71 - 8.83 | 8.83 - 8.9 |
| Close: | 8.95 - 9.14 | 9.14 - 9.25 |
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Tue, 03 Mar 2026
Kalaris Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview - TradingView
Sat, 21 Feb 2026
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therape - GuruFocus
Wed, 18 Feb 2026
Insider Stock Purchases: February 18, 2026 | KLRS Stock News - Quiver Quantitative
Tue, 17 Feb 2026
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares - Investing.com
Tue, 17 Feb 2026
Kalaris Therapeutics (NASDAQ:KLRS) Director Acquires $5,000,005.74 in Stock - MarketBeat
Tue, 17 Feb 2026
Samsara Opportunity Fund ups Kalaris Therapeutics (KLRS) stake with 479,847-share buy - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 96.7 (%) |
| Shares Short | 909 (K) |
| Shares Short P.Month | 540 (K) |
| EPS | -38.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.24 |
| PEG Ratio | 0 |
| Price to Book value | 4.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|